

ABSTRACT OF THE DISCLOSURE

The *in vivo* circulating life and/or absorption of cationic therapeutic proteins, including but not
5 limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.